Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Pay vs Performance Disclosure [Line Items] Statistical Measurement [Domain] Statistical Measurement [Domain] Inventory valuation reserves Inventory Valuation Reserves Research and development Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent November 2021 Share Repurchase Program Share Repurchase Program, November 2021 [Member] Share Repurchase Program, November 2021 Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Number of IPR filed Number of Inter Parties Review (IPR) Petitions Filed Number of Inter Parties Review (IPR) Petitions Filed Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Deferred costs Other Inventory, Net of Reserves Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] '226 and '992 Patents '226 Patent And '992 Patent [Member] '226 Patent And '992 Patent Investment, Name [Axis] Investment, Name [Axis] Total other income (expense) Nonoperating Income (Expense) Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Sonoma Biotherapeutics, Inc. Sonoma Biotherapeutics, Inc. [Member] Sonoma Biotherapeutics, Inc. Proceeds from issuance of Common Stock Proceeds from Issuance of Common Stock Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] (Decrease) increase in deferred revenue Increase (Decrease) in Contract with Customer, Liability Concentration Risk [Line Items] Concentration Risk [Line Items] Project [Domain] Project [Domain] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Preferred Stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none Preferred Stock, Value, Issued Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Net income per share - diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Receivable [Domain] Receivable [Domain] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Treasury stock (in shares) Beginning Balance, treasury (in shares) Ending Balance, treasury (in shares) Treasury Stock, Common, Shares Sales-based milestones earned Sales-Based Milestone Earned [Member] Sales-Based Milestone Earned Trading Symbol Trading Symbol Bonnie L. Bassler, Ph.D. [Member] Bonnie L. Bassler, Ph.D. McKesson Corporation McKesson Corporation [Member] McKesson Corporation [Member] Evkeeza Evkeeza [Member] Evkeeza Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Maturities after five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Long-term debt fair value Long-Term Debt, Fair Value Net income Net income Net income - basic and diluted Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Payments for Libtayo intangible asset Payments To Acquire Intangible Assets1 Payments To Acquire Intangible Assets1 Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Corporate bonds Corporate bonds Corporate bonds Corporate Bond Securities [Member] Property, plant, and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Libtayo LIBTAYO Net Product Sales [Member] LIBTAYO Net Product Sales [Member] Repurchases of Common Stock Stock Repurchased During Period, Value Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Equity, Attributable to Parent [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Deferred revenue Contract with Customer, Liability Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of goods, collaboration and contract manufacturing Cost of Goods and Services Sold Reimbursement for manufacturing of ex-U.S. commercial supplies Reimbursement For Manufacturing Of ex-Commercial Supplies [Member] Reimbursement For Manufacturing Of ex-Commercial Supplies Executive Category: Executive Category [Axis] Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations EYLEA EYLEA Net Product Sales [Member] Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions. Regeneron's share of profits in connection with commercialization of EYLEA outside the United States Net Profit In Connection With Commercialization [Member] Net Profit In Connection With Commercialization [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Marketable securities Marketable Securities, Current Name Forgone Recovery, Individual Name Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Other Other [Member] Other Issuance/distribution of Common Stock for 401(k) Savings Plan Stock Issued/Distributed During Period, Value, Employee Benefit Plan Stock Issued/Distributed During Period, Value, Employee Benefit Plan Certificates of deposit Certificates of deposit Certificates of Deposit [Member] Asset Acquisition [Domain] Asset Acquisition [Domain] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Decrease in accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Legal Matters Legal Costs, Policy [Policy Text Block] SG&A expense Selling, General and Administrative Expenses [Member] Unrealized (loss) gain on debt securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Measurement Frequency [Axis] Measurement Frequency [Axis] Marketable Securities, Based on Contractual Maturity Dates Investments Classified by Contractual Maturity Date [Table Text Block] Restricted cash included in Prepaid expenses and other current assets Restricted Cash and Cash Equivalents, Current Total adjustments Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Income Statement Location [Axis] Income Statement Location [Axis] Percentage of trial costs required to be funded by collaborating party Percentage of Trial Costs Required To Be Funded By Collaborating Party Percentage of Trial Costs Required To Be Funded By Collaborating Party Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Classification of Investment [Axis] Classification of Investment [Axis] This element represents the general categories of investments, which may be classified as Unrestricted or Restricted. Huda Y. Zoghbi, M.D. [Member] Huda Y. Zoghbi, M.D. Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Product and Service [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Other Other Collaboration Agreements [Member] Other Collaboration Agreements Besse Medical, a subsidiary of AmerisourceBergen Corporation Besse Medical [Member] Besse Medical [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Increase in inventories Increase (Decrease) in Inventories (R&D expense)/Reduction of R&D expense Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stock options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Trading Arrangement: Trading Arrangement [Axis] Levels of twelve-month sales at which sales milestone payments would be received Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received Levels Of Twelve Month Sales At Which Sales Milestone Payments Would Be Received PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Entity Shell Company Entity Shell Company Restatement Determination Date Restatement Determination Date Other operating income Other Operating Income (Expense) [Member] Sanofi Sanofi [Member] Sanofi Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash shown in the Condensed Consolidated Statement of Cash Flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Roche Collaboration Agreement Roche Collaboration Agreement [Member] Roche Collaboration Agreement Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Fair Value - 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common Stock, shares issued (in shares) Common Stock, Shares, Issued Deferred revenue Contract with Customer, Liability, Current Treasury Stock, at cost; 24.5 shares in 2023 and 22.6 shares in 2022 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Assets, Fair Value Disclosure, Total Assets, Fair Value Disclosure Unrealized Loss - Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Asset acquisition, assets acquired and liabilities assumed, net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Selling, general, and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Collaboration, License, and Other Agreements Collaborative Arrangement Disclosure [Text Block] Stock options Employee Stock Option [Member] Amounts recognized in connection with up-front payments received Amounts Recognized In Connection With Up-Front Payments [Member] Amounts Recognized In Connection With Up-Front Payments [Member] Class A Stock Common Class A [Member] Total Expenses Costs and Expenses Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Sales-Based Milestone One Sales-Based Milestone One [Member] Sales-Based Milestone One Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Total cost of shares Treasury Stock, Value, Acquired, Cost Method Marketable securities Marketable Securities, Noncurrent Reimbursement of R&D expenses Reimbursement Of Research And Development Expenses [Member] Reimbursement Of Research And Development Expenses [Member] Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Receivable Type [Axis] Receivable Type [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items, net Other Noncash Income (Expense) Reimbursement of commercialization-related expenses Reimbursement Of Commercialization-Related Expenses [Member] Reimbursement Of Commercialization-Related Expenses Restricted cash included in Other noncurrent assets Restricted Cash, Noncurrent Customer concentration risk Customer Concentration Risk [Member] Increase (decrease) in accounts payable, accrued expenses, and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Statements of Operations Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Issuance of Common Stock for equity awards granted under long-term incentive plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Cash consideration for Stock Purchase Agreement Payments Made To Acquire Equity Within A Collaboration Agreement Payments Made To Acquire Equity Within A Collaboration Agreement Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount (R&D expense)/Reduction of R&D expense Research And Development Expenses And Reduction of Research And Development Expense [Member] Research And Development Expenses And Reduction of Research And Development Expense Entity Tax Identification Number Entity Tax Identification Number Inventories Total Inventories Inventory, Net Purchases of marketable and other securities Payments to Acquire Marketable Securities Statistical Measurement [Axis] Statistical Measurement [Axis] ROW Rest Of World [Member] Rest Of World Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total Shareholder Return Amount Total Shareholder Return Amount Repurchases of Common Stock Payments for Repurchase of Common Stock Net product sales Product [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Apotex Inc. Apotex Inc. [Member] Apotex Inc. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Cost of goods sold Cost Of Goods Sold [Member] Cost Of Goods Sold Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Regeneron's obligation for its share of Sanofi commercial expenses Regeneron's Share Of Commercial Expenses [Member] Regeneron's Share Of Commercial Expenses Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sanofi Collaboration Agreement, Antibody Sanofi Collaboration Agreement, Antibody [Member] Sanofi Collaboration Agreement, Antibody [Member] Common Stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Common Stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Equity securities Equity Securities, FV-NI, Current Customer [Domain] Customer [Domain] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective income tax rate Effective Income Tax Rate Reconciliation, Percent EYLEA EYLEA Aflibercept Injection [Member] EYLEA Aflibercept Injection Sovereign bonds Sovereign bonds Sovereign Debt Securities [Member] Acquired in-process research and development in connection with asset acquisition Acquired In-Process Research And Development, Asset Acquisition Acquired In-Process Research And Development, Asset Acquisition Total liabilities Liabilities Asset Acquisition [Axis] Asset Acquisition [Axis] Interim Financial Statements Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Increase in prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Fair Value - Total Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Deferred revenue Contract with Customer, Liability, Noncurrent Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Number of ex parte reexamination requests Loss Contingency, Ex Parte Reexamination, Filed, Number Loss Contingency, Ex Parte Reexamination, Filed, Number Common stock Common Stock, Value, Issued Fair Value - Less than 12 Months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Maturities after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Legal Matters Legal Matters and Contingencies [Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Unrestricted Unrestricted [Member] Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements. Milestone Type [Domain] Milestone Type [Domain] Milestone Type [Domain] Total current assets Assets, Current Schedules of sales to customers as percentage of total gross product revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Asset acquisition, net of cash acquired Payments for Asset Acquisition Payments for Asset Acquisition Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Shares Repurchased Class of Treasury Stock [Table Text Block] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Share repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Repurchases of Common Stock (in shares) Stock Repurchased During Period, Shares PEO Name PEO Name Concentration risk, percentage Concentration Risk, Percentage Regeneron's share of profits in connection with commercialization Share Of Profit (Losses) In Connection With Commercialization [Member] Share Of Profit (Losses) In Connection With Commercialization [Member] Preferred Stock, shares authorized (in shares) Preferred Stock, Shares Authorized U.S. government and government agency obligations U.S. government and government agency obligations U.S. government and government agency obligations US Treasury and Government [Member] Share Repurchase Program, January 2023 Share Repurchase Program, January 2023 [Member] Share Repurchase Program, January 2023 Preferred Stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Restricted Restricted [Member] Restricted [Member] Asset-backed securities Asset-Backed Securities [Member] Inmazeb Inmazeb [Member] Inmazeb Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Andrew J. Murphy, Ph.D. [Member] Andrew J. Murphy, Ph.D. Depreciation and amortization Depreciation, Depletion and Amortization Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Other operating (income) expense, net Other Operating Income (Expense), Net Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Total stockholders' equity Beginning Balance Ending Balance Equity, Attributable to Parent Commercial paper Commercial paper Commercial Paper [Member] Accrued contingent consideration for Libtayo intangible asset Noncash or Part Noncash Acquisition, Intangible Assets Acquired Restricted stock awards and restricted stock units Restricted Stock [Member] Milestone Type [Axis] Milestone Type [Axis] Milestone Type Loss on foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Securities owned not readily marketable Equity Securities without Readily Determinable Fair Value, Amount Revenue, remaining performance obligation, variable consideration amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Cost of collaboration and contract manufacturing Collaboration and Contract Manufacturing [Member] Collaboration and Contract Manufacturing [Member] Preferred Stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Capital expenditures Payments to Acquire Productive Assets Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] One-time payment in connection with change in Japan arrangement One-time Payment in Connection With Change in Japan Arrangement [Member] One-time Payment in Connection With Change in Japan Arrangement Title Trading Arrangement, Individual Title Gross product revenue Gross Product Revenue [Member] Gross Sales Revenue [Member] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Income Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Alnylam Pharmaceuticals, Inc. Collaboration Agreement, Eye Program Alnylam Pharmaceuticals, Inc. Collaboration Agreement, Eye Program [Member] Alnylam Pharmaceuticals, Inc. Collaboration Agreement, Eye Program Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Upfront payment made Upfront Payment Made Upfront payment made under a collaboration agreement Minimum Minimum [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Alnylam Pharmaceuticals, Inc. Collaboration Agreement Alnylam Pharmaceuticals, Inc. Collaboration Agreement [Member] Alnylam Pharmaceuticals, Inc. Collaboration Agreement [Member] Percentage share of profits to reimburse collaborating party Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs Percentage Of Quarterly Profits Required To Be Paid For Reimbursement Of Development Costs Exercise Price Award Exercise Price Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Ronapreve Ronapreve [Member] Ronapreve Payments in connection with Common Stock tendered for employee tax obligations Payment, Tax Withholding, Share-Based Payment Arrangement Other revenue Product and Service, Other [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Purchase of preferred stock Payments to Acquire Interest in Subsidiaries and Affiliates Retained Earnings Retained Earnings [Member] Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones Royalty payment to collaborating party, percentage of net product sales Royalty Payment to Collaborating Party, Percentage of Net Product Sales Royalty Payment to Collaborating Party, Percentage of Net Product Sales Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Period for achieving sales target for milestone payment, rolling basis Period for Achieving Sales Target for Milestone Payment, Rolling Basis Period for Achieving Sales Target for Milestone Payment, Rolling Basis Total liabilities and stockholders' equity Liabilities and Equity Amortized Cost Basis Debt Securities, Available-for-Sale, Amortized Cost Other income (expense): Nonoperating Income (Expense) [Abstract] Other noncurrent assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement [Member] Alnylam Pharmaceuticals, Inc. Stock Purchase Agreement [Member] Unrealized gain on cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net income per share - basic (in dollars per share) Earnings Per Share, Basic Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Alnylam Pharmaceuticals, Inc. Collaboration Agreement, CNS Program Alnylam Pharmaceuticals, Inc. Collaboration Agreement, CNS Program [Member] Alnylam Pharmaceuticals, Inc. Collaboration Agreement, CNS Program Arrangement Duration Trading Arrangement Duration Fair Value and Unrealized Losses of Marketable Securities Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Sales Milestone Three Sales Milestone Three [Member] Sales Milestone Three Sales-Based Milestone Two Sales-Based Milestone Two [Member] Sales-Based Milestone Two Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] '631 Patent '631 Patent [Member] '631 Patent Remaining authorized repurchase amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Sales or maturities of marketable and other securities Proceeds from Sale and Maturity of Marketable Securities Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Total Available-for-sale debt securities Debt Securities, Available-for-Sale Sales Milestone Five Sales Milestone Five [Member] Sales Milestone Five Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Checkmate Pharmaceuticals, Inc. Checkmate Pharmaceuticals, Inc. [Member] Checkmate Pharmaceuticals, Inc. Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses [Member] Regeneron's Obligation Of Research And Development Expenses, Net of Reimbursement Of Research And Development Expenses Up-front payment to collaborating party Up-Front Payment to Collaborating Party Up-Front Payment to Collaborating Party Compensation Amount Outstanding Recovery Compensation Amount Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Additional paid-in capital Additional Paid in Capital Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Reimbursement for manufacturing of commercial supplies Reimbursement for manufacturing of ex-U.S. commercial supplies Reimbursement For Manufacturing Of Commercial Supplies [Member] Reimbursement For Manufacturing Of Commercial Supplies [Member] Statement of Cash Flows Cash Flow, Supplemental Disclosures [Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Percentage of share of profits used to reimburse collaborating party for trial costs Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs Percentage of Share of Profits Used to Reimburse Collaborating Party for Trial Costs Insider Trading Arrangements [Line Items] Losses on marketable and other securities, net Marketable and Other Securities, Gain (Loss) Marketable and Other Securities, Gain (Loss) Issuance of Common Stock for equity awards granted under long-term incentive plans (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Net unrealized losses Equity Securities, FV-NI, Unrealized Gain (Loss) Collaboration revenue Collaboration Revenue [Member] Collaboration Revenue Adjustment to Compensation, Amount Adjustment to Compensation Amount Classification of Investment [Domain] Classification of Investment [Domain] Provides general categories of investments for which information is required or determined to be disclosed. Praluent Praluent Net Product Sales [Member] Praluent Net Product Sales Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Schedule of assets measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Finance lease liabilities Finance Lease, Liability, Noncurrent Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Income tax expense Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Outside United States Non-US [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Cash and Cash Equivalents [Abstract] Bayer Bayer Collaboration Agreement [Member] Bayer Collaboration Agreement [Member] Schedule of product sales Schedule of collaborative revenue Disaggregation of Revenue [Table Text Block] Unrealized Loss - 12 Months or Greater Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Sonoma Biotherapeutics, Inc. Collaboration Agreement Sonoma Biotherapeutics, Inc. Collaboration Agreement [Member] Sonoma Biotherapeutics, Inc. Collaboration Agreement Celltrion, Inc. Celltrion, Inc. [Member] Celltrion, Inc. Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventories Inventory Disclosure [Text Block] Revenues Up-front payment to be made to collaborator Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Regulatory Milestone Regulatory Milestone [Member] Regulatory Milestone Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Deferred income taxes Increase (Decrease) in Deferred Income Taxes Unrealized Loss - Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Common Stock tendered upon exercise of stock options and vesting of restricted stock for employee tax obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Maturities within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Number of shares (in shares) Treasury Stock, Shares, Acquired Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt Long-Term Debt, Excluding Current Maturities Weighted average shares outstanding - diluted (in shares) Weighted average shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of accounts receivable and deferred revenue information Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Trade accounts receivable Trade Accounts Receivable [Member] Product Sales Revenue from Contract with Customer [Text Block] Company Selected Measure Amount Company Selected Measure Amount Additional Paid-in Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Collaborative arrangement additional payment eligible Revenue Collaborative Arrangement, Additional Payment Eligible, Milestone Collaborative Arrangement, Additional Payment Eligible, Milestone Share Repurchase Program [Axis] Share Repurchase Program [Axis] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Stock-based compensation charges APIC, Share-Based Payment Arrangement, Increase for Cost Recognition '338 Patent And '069 Patent '338 Patent And '069 Patent [Member] '338 Patent And '069 Patent U.S. UNITED STATES Measured on a recurring basis Fair Value, Recurring [Member] Other noncurrent liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Summary of Non-Cash Investing and Financing Activities Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Number of milestones Collaborative Arrangement, Number Of Milestone Payments Collaborative Arrangement, Number Of Milestone Payments Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Project [Axis] Project [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted average shares outstanding - basic (in shares) Weighted average shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Income from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Sanofi Collaboration Agreement, Immuno-oncology Sanofi Collaboration Agreement, Immuno-oncology Sanofi Collaboration Agreement, Immuno-oncology [Member] Sanofi Collaboration Agreement, Immuno-oncology [Member] Regeneron's obligation for Sanofi's share of Libtayo U.S. gross profits Sanofi's Share of Libtayo U.S. Gross Profits [Member] Sanofi's Share of Libtayo U.S. Gross Profits [Member] Revenues: Revenues [Abstract] Statements of Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Acquired in-process research and development Acquired In-Process Research and Development Acquired In-Process Research and Development Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Available-for-sale Debt Securities Debt Securities, Available-for-Sale [Table Text Block] Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&D Expenses [Member] Reimbursement Of Research And Development Expenses, Net Of Obligation For Share Of R&D Expenses